The company reported revenues of $443.7 million and organic growth of 3 percent, driven in large part by strength in its scientific instruments business.
Waters said the acquisition is part of a strategy to develop simpler, more streamlined mass spec workflows that will be accessible to non-expert users.
The company posted Q2 revenues of $596.2 million, up from $558.3 million in Q2 2017, short of the average Wall Street estimate of $598 million.
As part of the deal, Waters has also placed a Synapt G2-Si mass spec instrument at Purdue University to help advance research applications for DESI.
The study, which coupled FAIMS to an Orbitrap mass spec, indicates the technology could streamline proteomics experiments without sacrificing depth of analysis.
Dian selected the MassArray system as its platform of choice for molecular genetic testing and will commercialize it and Agena's DNA applications and products.
The researchers identified 669 and quantified 332 proteins in single cells, making this one of the most comprehensive mass spec-based experiments of its kind.
The reagents are intended for use in a recently developed workflow designed to address the precursor interference issue that has troubled the labeling method.
The PMSC, which formally opened last week, offers mass spectrometry and sequencing resources to help customers develop robust and scalable workflows.
With the release of its Q Exactive UHMR system and a new $130 million NIH program, the company sees opportunity to expand use of its cryo-EM and mass spec techs.
Major releases were relatively sparse at ASMS as many vendors focused instead on the development of applications and workflows for their existing platforms.
The study combined large-scale protein post-translational modification datasets with protein-protein interaction data to profile cell signaling in lung cancer.
Developed in the lab of Max Planck's Matthias Mann, the approach adjusts the sampling of ions during the initial scan to boost assay sensitivity and reproducibility.
The company reported total revenues of $431.7 million for the three months ended March 31, beating analysts' consensus estimate of $417.4 million.
Using a mass cytometry method called EpiTOF, researchers profiled histone modifications and variants in a range of immune cell types across individuals of different ages.
Based on the strong first quarter results, the company raised its revenue and earnings guidance for the year.
Organic revenues were up 2 percent, as the company saw solid demand among its pharma customers but a decline in sales of its mass spectrometry instruments.
The study used analysis of intact proteins to identify mutation-linked post-translational modifications involved in KRAS activation and membrane attachment.
At the AACR annual meeting, researchers highlighted genomics- and proteomics-informed research aimed at establishing more effective, targeted immunotherapies.
While mass spec-based single-cell proteomics is still in its infancy, recently developed methods allow the ID of thousands of proteins at the single-cell level.
Microsoft co-founder Paul Allen also contributed to brain research, NPR reports.
The New York Times reports on the shifting interpretations of what some genetic variants mean over time.
In Cell this week: investigation of metastatic tumor evolution, more than 16,000 genetic variants introduced into the budding yeast model organism, and more.
MIT's Technology Review reports on Genentech's pursuit of personalized cancer vaccines.